Multi-omics genetic study revealing ferroptosis regulator CTSB driving prostate cancer progression by modulating the immune microenvironment
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-025-04593-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Jucai Song und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Andrology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450003, Henan, China. Hauptthemen laut MEDLINE: Ferroptosis, Prostatic Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: Henan Province Traditional Chinese Medicine Scientific Research Special Project, National Traditional Chinese Medicine Advantageous Specialty Construction Project.
Abstract (Originalsprache)
The progression and mechanisms of drug resistance in prostate cancer are highly complex, with the ferroptosis pathway playing a critical role. We utilized multi-omics Mendelian randomization (MR) to assess the genetic causal link between ferroptosis gene/protein expression and prostate cancer, investigating potential mediation by 731 immune cell types. Furthermore, differential expression analysis, immune infiltration analysis, single-cell RNA sequencing, gene set enrichment analysis (GSEA), and drug prediction were integrated for multidimensional validation and mechanistic insight. Our results identified cathepsin B (CTSB) as a key causal risk factor associated with iron death in the development of prostate cancer (odds ratio (OR) > 1, p 0.95) ruled out confounding biases. Mediation MR analysis revealed that CTSB partially mediates its carcinogenic effects by regulating various immune cells, such as PD-L1 + monocytes and CD45 + T cells (OR > 1, p 0, p 2, false discovery rate (FDR) < 0.001). Drug prediction analyses suggested that targeting CTSB (e.g., with bortezomib) in combination with immunotherapy may represent a novel therapeutic strategy. This study provides the first evidence of the causal role of iron death-immune interactions in prostate cancer, offering new targets for precision treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Andrology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450003, Henan, China.
- The First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, 450046, Henan, China.
- Department of Andrology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450003, Henan, China. wangzulong123@126.com.
Förderung
- Henan Province Traditional Chinese Medicine Scientific Research Special Project
- National Traditional Chinese Medicine Advantageous Specialty Construction Project
Zitieren
APA
Song, J., Zhang, Q., Ma, M., Ma, P., Chen, R., & Wang, Z. (2026). Multi-omics genetic study revealing ferroptosis regulator CTSB driving prostate cancer progression by modulating the immune microenvironment. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04593-y
Vancouver
Song J, Zhang Q, Ma M, Ma P, Chen R, Wang Z. Multi-omics genetic study revealing ferroptosis regulator CTSB driving prostate cancer progression by modulating the immune microenvironment. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04593-y
BibTeX
@article{Song2026,
author = {Song, Jucai and Zhang, Qi and Ma, Miaomiao and Ma, Peng and Chen, Rubing and Wang, Zulong},
title = {Multi-omics genetic study revealing ferroptosis regulator CTSB driving prostate cancer progression by modulating the immune microenvironment},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-025-04593-y}
}
EUVIMED